Information Provided By: 
Fly News Breaks for June 3, 2015
ESPR
Jun 3, 2015 | 07:51 EDT
JMP Securities believes that investors are overly worried that the U.S. and EU will require Esperion to conduct a pre-approval cardiovascular outcomes trial for ETC-1002. The firm thinks that two upcoming catalysts could alleviate this concern, i.e. an FDA panel meeting next week and data from a Phase 2 trial of ETC-1002, due out by the end of Q3. The firm says that the recent weakness in the stock has created a buying opportunity.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
